Vanda Pharmaceuticals - Worst Pharma Stocks of 2007

Company: Vanda Pharmaceuticals
Starting stock price: $24.83
Ending stock price: $6.88
Percent Change: -72.29%

Details: Vanda Pharmaceuticals has three in-development candidates, all focused on nervous system disorders. In September 2007, it filed a NDA for its antipsychotic med iloperidone. In a clinical trial the drug showed efficacy against schizophrenia symptoms but some developed an irregular heartbeat; the company plans to couple genetic testing with its drug to identify those likely to experience the heart problem. Its two other possibles are targeted at sleep and mood problems. One is in Phase III and the other recently wrapped up a Phase II study.

More News:
Vanda gains on late-stage sleep trial data. Report

Vanda Pharmaceuticals - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.